GLPwatch
GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
Lancet · 2025
Last updated 2026-05-28| Journal | Lancet, 2025 |
|---|---|
| Citations | 4 |
| Molecules | amycretin |
| Conditions studied | Obesity |
Full record and abstract on PubMed 40550232 ↗
Related research
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
- The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.